Jefferies analyst Akash Tewari maintained a Buy rating on Alkermes (ALKS – Research Report) today and set a price target of $42.00. The company’s shares closed last Friday at $27.31.
According to TipRanks, Tewari is a 5-star analyst with an average return of 39.7% and a 62.96% success rate. Tewari covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, BioMarin Pharmaceutical, and Horizon Therapeutics.
Alkermes has an analyst consensus of Moderate Buy, with a price target consensus of $32.00.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $32.79 and a one-year low of $21.75. Currently, Alkermes has an average volume of 1.65M.
Based on the recent corporate insider activity of 43 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ALKS in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Alkermes Plc is a biopharmaceutical company, which engages in the development, research, and commercialization of medicines that are designed to address unmet medical needs of patients in major therapeutic areas. Its products include Aristada, which is used for the treatment of schizophrenia in adults; and Vivitrol, which is an injectable medication for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence, following opioid detoxification. The company was founded on May 4, 2011 and is headquartered in Dublin, Ireland.
Read More on ALKS:
- Alkermes price target raised to $28 from $27 at BofA
- Alkermes reports interim award in arbitration proceedings with Janssen
- Piper recommends ‘down market cap’ biotech exposure for 2023
- Alkermes positioned for ‘considerable value creation,’ says Piper Sandler
- Alkermes management to meet with Piper Sandler
